Posts tagged Ariad Pharmaceuticals Inc.


Stock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces Submission of MAA for Brigatinib to the EMA

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the submission of a Marketing Authorization Application (MAA) for its …

Healthcare Analysts Weigh in on Two Buzzing Stocks: Ariad Pharmaceuticals, Inc. (ARIA), EXACT Sciences Corporation (EXAS)

Ariad Pharmaceuticals, Inc. Investors in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) should be smiling from ear to …

Stock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Enters Agreement to Be Acquired by Takeda Pharmaceutical for $5.2 Billion

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it has entered into a definitive agreement to be acquired …

William Blair Speculates on Ariad Pharmaceuticals, Inc. (ARIA) Following Updated ALTA Data

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) recently presented updated data from the pivotal ALTA trial of brigatinib …

Stock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces Data Presentations at American Society of Hematology Meeting

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of clinical and translational studies on Iclusig®(ponatinib), its …

Stock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Presents Updated Brigatinib Data at the World Conference on Lung Cancer

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced clinical data on brigatinib, its investigational anaplastic lymphoma kinase (ALK) …

JMP’s Michael King Neutral on Ariad Pharmaceuticals, Inc. (ARIA) Despite Full FDA Approval for Iclusig

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released yesterday morning the FDA’s decision approving the firm’s pipeline drug …

Company Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces FDA Full Approval and Label Update for Iclusig

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the U.S. Food and Drug Administration (FDA) has granted …

Show More